Barbara A. Cornblatt

Last updated
Barbara A. Cornblatt
Alma materBaruch College, New School University
Occupation(s)Professor at Hofstra Northwell School of Medicine, Investigator at Center for Psychiatric Neuroscience and The Feinstein Institute for Medical Research, Director of the Recognition and Prevention Program
Awards Joseph Zubin Memorial Fund Award (1996)

Barbara A. Cornblatt is Professor of Psychiatry and Molecular Medicine at Hofstra Northwell School of Medicine. [1] She is known for her research on serious mental disorders, with a specific focus on psychosis and schizophrenia. [2] [3] Her efforts to find treatments to help youth with mental illness led to the development of the Recognition and Prevention Program, which she founded in 1998. [4]

Contents

Cornblatt was awarded the Joseph Zubin Memorial Fund Award in 1996. [5] She served as president of the Society for Research in Psychopathology (2000–01). [6]

Biography

Cornblatt received an MBA degree in industrial psychology at Baruch College, City University of New York in 1977 and a Ph.D. in experimental psychology from New School University in 1978. [1]

Cornblatt's research program, including projects focusing on cognitive behavioral social skills training for youth at risk of psychosis, [7] predictors and mechanisms of conversion to psychosis, [8] and characterization of prodromal schizophrenia, [9] has been funded by the National Institute of Mental Health of the National Institutes of Health. She worked on North American Prodrome Longitudinal Study (NAPLS-1), a large multisite longitudinal study focusing on the earliest stages of psychotic illness, [10] with prominent clinical psychologists and psychiatrists including Tyrone Cannon, Elaine F. Walker, and Thomas McGlashan. [11] [12]

Research

Towards a Psychosis Risk Blood Diagnostic for Persons Experiencing High-Risk Symptoms: In this study, the researchers looked at different analytes found in human blood plasma. These plasma analytes reflected inflammation, oxidative stress, hormones, and metabolism. It was discovered that individuals who are at a high-risk for psychosis have high levels of inflammation, oxidative stress, and hormone imbalances. [13]

Cortisol Level and Risk for Psychosis: Researchers tested the cortisol contents of saliva in 256 individuals. It was discovered that patients that were at a higher risk of psychosis, or already had the diagnosis, had increased cortisol levels. This study suggests the need for future research focusing on the hormone levels of individuals with, or at risk of, psychosis. [14]

Functional development in clinical high risk youth: Prediction of schizophrenia versus other psychotic disorders: This study was a follow-up study involving participants from the NAPLS-1 study. Researchers checked for three different signs in their patients: psychosis-risk symptoms present at baseline (these plasma analytes reflected inflammation, oxidative stress, hormones, and metabolism), onset of psychosis during the two and a half-year follow-along period of NAPLS-1, and psychotic disorder diagnosis from the Diagnostic and Statistical Manual of Mental Disorders (DSM). The study showed that people in early adolescence who showed poor social indicators were four times as likely to develop schizophrenia. Those in their late adolescence with poor social indicators were five times as likely to develop schizophrenia. [15]

Impaired Attention, Genetics, and the Pathophysiology of Schizophrenia: This study found that the use of a Continuous Performance Test (CPT) is a cost-effective way to screen for the impaired attention that is often present in those with diagnosed schizophrenia and those at genetic risk for developing schizophrenia. Over 40 studies that used CPT testing in various formats were analyzed to draw this conclusion. The resulting recommendation is that the use of a Continuous Performance Test would be a valuable way to screen for the disorder, the results of which could then be used as a precursor for a patient entering preventative intervention programs. [16]

Representative publications

Related Research Articles

<span class="mw-page-title-main">Schizophrenia</span> Mental disorder with psychotic symptoms

Schizophrenia is a mental disorder characterized variously by hallucinations, delusions, disorganized thinking and behavior, and flat or inappropriate affect. Symptoms develop gradually and typically begin during young adulthood and are never resolved. There is no objective diagnostic test; diagnosis is based on observed behavior, a psychiatric history that includes the person's reported experiences, and reports of others familiar with the person. For a diagnosis of schizophrenia, the described symptoms need to have been present for at least six months or one month. Many people with schizophrenia have other mental disorders, especially mood, anxiety, and substance use disorders, as well as obsessive–compulsive disorder (OCD).

<span class="mw-page-title-main">Olanzapine</span> Atypical antipsychotic medication

Olanzapine, sold under the brand name Zyprexa among others, is an atypical antipsychotic primarily used to treat schizophrenia and bipolar disorder. It is also sometimes used off-label for treatment of chemotherapy-induced nausea and vomiting and as an appetite stimulant. For schizophrenia, it can be used for both new-onset disease and long-term maintenance. It is taken by mouth or by injection into a muscle.

Schizoaffective disorder is a mental disorder characterized by symptoms of both schizophrenia (psychosis) and a mood disorder, either bipolar disorder or depression. The main diagnostic criterion is the presence of psychotic symptoms for at least two weeks without prominent mood symptoms. Common symptoms include psychosis, as well as mood episodes. Schizoaffective disorder can often be misdiagnosed when the correct diagnosis may be psychotic depression, bipolar I disorder, schizophreniform disorder, or schizophrenia. This is a problem as treatment and prognosis differ greatly for most of these diagnoses. Many people with schizoaffective disorder have other mental disorders including anxiety disorders.

Schizotypal personality disorder, also known as schizotypal disorder, is a cluster A personality disorder. The Diagnostic and Statistical Manual of Mental Disorders (DSM) describes the disorder specifically as a personality disorder characterized by thought disorder, paranoia, a characteristic form of social anxiety, derealization, transient psychosis, and unconventional beliefs.

Dr. Thomas McGlashan is an American professor of psychiatry at Yale University, well known for his academic contributions to the study of schizophrenia and other mental illnesses.

Schizophrenia is a neurodevelopmental disorder with no precise or single cause. Schizophrenia is thought to arise from multiple mechanisms and complex gene–environment interactions with vulnerability factors. Risk factors of schizophrenia have been identified and include genetic factors, environmental factors such as experiences in life and exposures in a person's environment, and also the function of a person's brain as it develops. The interactions of these risk factors are intricate, as numerous and diverse medical insults from conception to adulthood can be involved. Many theories have been proposed including the combination of genetic and environmental factors may lead to deficits in the neural circuits that affect sensory input and cognitive functions.

In medicine, a prodrome is an early sign or symptom that often indicates the onset of a disease before more diagnostically specific signs and symptoms develop. More specifically, it refers to the period between the first recognition of a disease's symptom until it reaches its more severe form. It is derived from the Greek word prodromos, meaning "running before". Prodromes may be non-specific symptoms or, in a few instances, may clearly indicate a particular disease, such as the prodromal migraine aura.

Early intervention in psychosis is a clinical approach to those experiencing symptoms of psychosis for the first time. It forms part of a new prevention paradigm for psychiatry and is leading to reform of mental health services, especially in the United Kingdom and Australia.

In psychiatry, catastrophic schizophrenia or schizocaria is an outdated term for a rare, acute form of schizophrenia leading to chronic psychosis and deterioration of the personality.

The diagnosis of schizophrenia, a psychotic disorder, is based on criteria in either the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, or the World Health Organization's International Classification of Diseases (ICD). Clinical assessment of schizophrenia is carried out by a mental health professional based on observed behavior, reported experiences, and reports of others familiar with the person. Diagnosis is usually made by a psychiatrist. Associated symptoms occur along a continuum in the population and must reach a certain severity and level of impairment before a diagnosis is made. Schizophrenia has a prevalence rate of 0.3-0.7% in the United States.

At risk mental state is the clinical presentation of those considered at risk of developing psychosis or schizophrenia. Such states were formerly considered treated as prodromes, emerging symptoms of psychosis, but this view is no longer prevalent as a prodromal period can not be confirmed unless the emergence of the condition has occurred.

Sex differences in schizophrenia are widely reported. Men and women exhibit different rates of incidence and prevalence, age at onset, symptom expression, course of illness, and response to treatment. Reviews of the literature suggest that understanding the implications of sex differences on schizophrenia may help inform individualized treatment and positively affect outcomes.

<span class="mw-page-title-main">Mary Cannon</span> Irish psychiatrist and research scientist

Mary Cannon is an Irish psychiatrist, research scientist, public figure, and former member of the Cannabis Risk Alliance. She has received the Royal Academy of Medicine in Ireland's "Doctors Award" for psychiatry and is among the most highly cited scientists in the world. Cannon is known for her views on cannabis, being described as 'anti-cannabis'. She is best known in the field of psychiatry for her study of the risk factors for mental illness in young people.

<span class="mw-page-title-main">Basic symptoms of schizophrenia</span> Subjective symptoms of schizophrenia

Basic symptoms of schizophrenia are subjective symptoms, described as experienced from a person's perspective, which show evidence of underlying psychopathology. Basic symptoms have generally been applied to the assessment of people who may be at risk to develop psychosis. Though basic symptoms are often disturbing for the person, problems generally do not become evident to others until the person is no longer able to cope with their basic symptoms. Basic symptoms are more specific to identifying people who exhibit signs of prodromal psychosis (prodrome) and are more likely to develop schizophrenia over other disorders related to psychosis. Schizophrenia is a psychotic disorder, but is not synonymous with psychosis. In the prodrome to psychosis, uncharacteristic basic symptoms develop first, followed by more characteristic basic symptoms and brief and self-limited psychotic-like symptoms, and finally the onset of psychosis. People who were assessed to be high risk according to the basic symptoms criteria have a 48.5% likelihood of progressing to psychosis. In 2015, the European Psychiatric Association issued guidance recommending the use of a subscale of basic symptoms, called the Cognitive Disturbances scale (COGDIS), in the assessment of psychosis risk in help-seeking psychiatric patients; in a meta-analysis, COGDIS was shown to be as predictive of transition to psychosis as the Ultra High Risk (UHR) criteria up to 2 years after assessment, and significantly more predictive thereafter. The basic symptoms measured by COGDIS, as well as those measured by another subscale, the Cognitive-Perceptive basic symptoms scale (COPER), are predictive of transition to schizophrenia.

Elaine F. Walker is a psychologist and professor whose research focuses on child and adolescent development, and changes in the brain due to adolescence. Other research interests includes the precursors and neurodevelopment aspects of schizophrenia and other serious mental disorders. She has taken part in writing over 250 articles and six books related to mental health and neuroscience. Walker is the Samuel Candler Dobbs Professor of Psychology and Neuroscience at Emory University.

Ming Tso Tsuang is an American psychiatrist and Distinguished Professor of Psychiatry at the University of California, San Diego. He is considered a pioneering researcher in the genetic epidemiology of schizophrenia and other severe mental disorders. Tsuang has authored and co-authored more than 600 publications and serves as founding and senior editor of the American Journal of Medical Genetics Part B.

<span class="mw-page-title-main">Zucker Hillside Hospital</span> Major teaching and psychiatric hospital

Zucker Hillside Hospital is a psychiatric facility in Glen Oaks, Queens, New York. It opened in 1926, relocated to its present address in 1941, and was renamed in 1999 to its present name.

Diana O. Perkins is an American professor at the University of North Carolina's (UNC) School of Medicine where she teaches psychiatry; she is a fellow with outreach roles. Her research involves early diagnosis and treatment of schizophrenia. She is noted for publishing a study that demonstrated that using a polygenic risk score (PRS) based on data from genome-wide association studies improved the psychosis risk prediction in persons meeting clinical high-risk criteria.

Carrie Elyse Bearden is an American psychologist and academic. She is a professor at the David Geffen School of Medicine, University of California, Los Angeles, and Director of the UCLA Center for the Assessment and Prevention of Prodromal States, a clinical research program for youth at high risk for psychotic disorders. She is most known for her research taking a ‘genetics first’ approach to study brain mechanisms underlying the development of serious mental illness. Her work has identified biological convergence between genetically and clinically defined high-risk populations.

<span class="mw-page-title-main">Osoresnontrine</span> Chemical compound

Osoresnontrine (BI-409306) is a phosphodiesterase 9 inhibitor in development for schizophrenia, attenuated psychosis syndrome, and Alzheimer's disease. A preclinical study suggested that it increases memory in rodents.

References

  1. 1 2 Cornblatt, Barbara. "Barbara A. Cornblatt, PhD, MBA – Investigator at The Feinstein Institute | Northwell Health". The Feinstein Institute for Medical Research.
  2. ↑ "Doctors Try a Bold Move Against Schizophrenia". archive.nytimes.com. Retrieved 2020-01-25.
  3. ↑ Carey, Benedict (2006-05-23). "A Career That Has Mirrored Psychiatry's Twisting Path". The New York Times. ISSN   0362-4331 . Retrieved 2020-01-25.
  4. ↑ "Recognition and Prevention Program - Understanding Psychosis". www.rapprogram.org.
  5. ↑ "Zubin Awards". www.wpic.pitt.edu. Retrieved 2020-01-25.
  6. ↑ "Society for Research in Psychopathology" . Retrieved 2020-01-25.
  7. ↑ Cornblatt, Barbara. "2/3-Cognitive Behavioral Social Skills Training for Youth at Risk of Psychosis". Grantome.
  8. ↑ Cornblatt, Barbara. "4/9-Predictors and Mechanisms of Conversion to Psychosis". Grantome.
  9. ↑ Cornblatt, Barbara. "Characterization of Prodromal Schizophrenia". Grantome.
  10. ↑ Addington, Jean; Liu, Lu; Buchy, Lisa; Cadenhead, Kristin S.; Cannon, Tyrone D.; Cornblatt, Barbara A.; Perkins, Diana O.; Seidman, Larry J.; Tsuang, Ming T.; Walker, Elaine F.; Woods, Scott W. (2015). "North American Prodrome Longitudinal Study (NAPLS 2): The Prodromal Symptoms". The Journal of Nervous and Mental Disease. 203 (5): 328–335. doi:10.1097/NMD.0000000000000290. ISSN   0022-3018. PMC   4417745 . PMID   25919383.
  11. ↑ Cannon, Tyrone D.; Cadenhead, Kristin; Cornblatt, Barbara; Woods, Scott W.; Addington, Jean; Walker, Elaine; Seidman, Larry J.; Perkins, Diana; Tsuang, Ming; McGlashan, Thomas; Heinssen, Robert (2008-01-01). "Prediction of Psychosis in Youth at High Clinical Risk: A Multisite Longitudinal Study in North America". Archives of General Psychiatry. 65 (1): 28–37. doi:10.1001/archgenpsychiatry.2007.3. ISSN   0003-990X. PMC   3065347 . PMID   18180426.
  12. ↑ Woods, Scott W.; Addington, Jean; Cadenhead, Kristin S.; Cannon, Tyrone D.; Cornblatt, Barbara A.; Heinssen, Robert; Perkins, Diana O.; Seidman, Larry J.; Tsuang, Ming T.; Walker, Elaine F.; McGlashan, Thomas H. (2009-09-01). "Validity of the Prodromal Risk Syndrome for First Psychosis: Findings From the North American Prodrome Longitudinal Study". Schizophrenia Bulletin. 35 (5): 894–908. doi:10.1093/schbul/sbp027. ISSN   0586-7614. PMC   2728816 . PMID   19386578.
  13. ↑ Perkins, Diana O.; Jeffries, Clark D.; Addington, Jean; Bearden, Carrie E.; Cadenhead, Kristin S.; Cannon, Tyrone D.; Cornblatt, Barbara A.; Mathalon, Daniel H.; McGlashan, Thomas H.; Seidman, Larry J.; Tsuang, Ming T. (March 2015). "Towards a Psychosis Risk Blood Diagnostic for Persons Experiencing High-Risk Symptoms: Preliminary Results From the NAPLS Project". Schizophrenia Bulletin. 41 (2): 419–428. doi:10.1093/schbul/sbu099. ISSN   0586-7614. PMC   4332942 . PMID   25103207.
  14. ↑ Walker, Elaine F.; Trotman, Hanan D.; Pearce, Brad D.; Addington, Jean; Cadenhead, Kristin S.; Cornblatt, Barbara A.; Heinssen, Robert; Mathalon, Daniel H.; Perkins, Diana O.; Seidman, Larry J.; Tsuang, Ming T.; Cannon, Tyrone D.; McGlashan, Thomas H.; Woods, Scott W. (September 15, 2013). "Cortisol Levels and Risk for Psychosis: Initial Findings from the North American Prodrome Longitudinal Study". Biological Psychiatry. 74 (6): 410–417. doi:10.1016/j.biopsych.2013.02.016. PMC   3707958 . PMID   23562006.
  15. ↑ Tarbox, Sarah I.; Addington, Jean; Cadenhead, Kristin S.; Cannon, Tyrone D.; Cornblatt, Barbara A.; Perkins, Diana O.; Seidman, Larry J.; Tsuang, Ming T.; Walker, Elaine F.; Heinssen, Robert; McGlashan, Thomas H.; Woods, Scott W. (January 30, 2014). "Functional development in clinical high risk youth: Prediction of schizophrenia versus other psychotic disorders". Psychiatry Research. 215 (1): 52–60. doi:10.1016/j.psychres.2013.10.006. PMC   3946851 . PMID   24200216.
  16. ↑ Cornblatt, Barbara A.; Keilp, John G. (1994-01-01). "Impaired Attention, Genetics, and the Pathophysiology of Schizophrenia". Schizophrenia Bulletin. 20 (1): 31–46. doi:10.1093/schbul/20.1.31. ISSN   0586-7614.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.